Introduction
Buprenorphine is a long-acting partial mu-receptor agonist with a mean elimination half-life of 24-48 hours. It is available sublingual tablets (Subutex), sublintual/buccal film (Suboxone, Belbuca), transdermal patch (Butrans), and long-acting subcutaneous injection (Sublocade). Commonly it is used in combination with naloxone (Suboxone) to reduce the risk of abuse by injection – as naloxone is poorly absorbed sublingually but is biologically active when injected, inducing acute withdrawal in physically dependent individuals.
Several pharmacologic properties of buprenorphine make it an ideal medication to treat opioid use disorder, including partial agonism, ceiling effect, and high binding affinity.
PARTIAL AGONIST
Buprenorphine, unlike other opioids, is a partial agonist at the mu-receptor – which leads to incomplete receptor activation.
CEILING EFFECT:
At higher doses, the clinical effects of the buprenorphine level off. PET imaging studies demonstrate that at 16m daily dosing, approximately 80% of the mu-receptors are occupied, and at 32mg daily 84-98% receptor occupancy is achieved.
Most patients achieve stabilization at 16-24mg daily, though 32mg (and at times high) may be needed for patients using high-potency synthetic opioids.
Since the clinical effects level off, along with partial agonism, there is a lower abuse potential and a ceiling effect on respiratory depression when compared to other full-opioid agonists.
HIGH BINDING AFFINITY
Buprenorphine's affinity for the mu-opioid receptor is approximately 1.7 times that of hydromorphone, 5.4 times that of morphine, 6.7 times that of fentanyl, and 120 times that of oxycodone.
Higher binding affinity can lead to displacement of other opioids, including potent long-acting opioids, which can lead to precipitated withdrawal for patients who have developed physical dependence.
References
Harris MTH, Weinstein ZM, Walley AY. Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose: A Review. JAMA. Published online February 11, 2026. doi:10.1001/jama.2025.26348
Kan, D., Zweben, J., Stine, J., Kosten, T. R., McCance-Katz, E. F., & McCarthy, M. Pharmacological and Psychosocial Treatment for Opioid Use Disorder. In The ASAM Principles of Addiction Medicine (6th ed.), edited by S. C. Miller, D. A. Fiellin, R. N. Rosenthal, & R. Saitz (pp. 326-330). Wolters Kluwer.